Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Anders

Showing results (151-160 of 271) with videos related to

Pageof 28
Sort By:
Pediatric Blood & Cancer|June 8, 2007
Initial testing of cisplatin by the pediatric preclinical testing programMimi Tajbakhsh, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer|August 19, 2014
Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing programPeter J Houghton, Raushan T Kurmasheva, Dmitry Lyalin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupAdam J Lamble, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Pediatric Blood & Cancer|April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer|July 25, 2020
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortiumJonathan Gill, Wendong Zhang, Zhongting Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adultsE Anders Kolb, Brian H Kushner, Richard Gorlick, et al.
Pediatric Blood & Cancer|October 5, 2007
Initial testing of dasatinib by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pediatric Blood & Cancer|November 1, 2018
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology GroupMichael S Isakoff, Robert Goldsby, Doojduen Villaluna, et al.
Pediatric Blood & Cancer|July 31, 2010
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programStephen T Keir, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|February 8, 2011
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Richard Lock, et al.
Pageof 28

Showing results (151-160 of 271) with videos related to

Sort By:
Pageof 28
Pediatric Blood & Cancer|June 8, 2007
Initial testing of cisplatin by the pediatric preclinical testing programMimi Tajbakhsh, Peter J Houghton, Christopher L Morton, et al.
Pediatric Blood & Cancer|August 19, 2014
Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing programPeter J Houghton, Raushan T Kurmasheva, Dmitry Lyalin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupAdam J Lamble, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
Pediatric Blood & Cancer|April 26, 2007
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing programJohn M Maris, Joshua Courtright, Peter J Houghton, et al.
Pediatric Blood & Cancer|July 25, 2020
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortiumJonathan Gill, Wendong Zhang, Zhongting Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adultsE Anders Kolb, Brian H Kushner, Richard Gorlick, et al.
Pediatric Blood & Cancer|October 5, 2007
Initial testing of dasatinib by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Peter J Houghton, et al.
Pediatric Blood & Cancer|November 1, 2018
A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology GroupMichael S Isakoff, Robert Goldsby, Doojduen Villaluna, et al.
Pediatric Blood & Cancer|July 31, 2010
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing programStephen T Keir, John M Maris, Richard Lock, et al.
Pediatric Blood & Cancer|February 8, 2011
Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing programE Anders Kolb, Richard Gorlick, Richard Lock, et al.
Pageof 28